Latest Conference Articles

The Need for and Realities of Biosimilars in Generating Health System Savings

Kelly Davio

May 15 2019

During the Biosimilars Commercialisation Summit 2019, held May 14-15 in Amsterdam, the Netherlands, among the key topics of discussion was the sustainability of the world’s healthcare systems and the need to create savings in order to continue to advance the treatment of cancer and chronic diseases.

Sandoz's Francisco Ballester Discusses Biosimilars in Emerging Markets

Kelly Davio

May 14 2019

During the inaugural Biosimilars Commercialisation Summit, held May 14-15, 2019, in Amsterdam, the Netherlands, Francisco Ballester, MBA, head of the international region for Sandoz, discussed some of the key considerations that biosimilar developers face in emerging markets with The Center for Biosimilars®.

Experts Share Their Experience of the Global Biosimilars Market

Kelly Davio

May 14 2019

This week, stakeholders from the legal, business, clinical, and development fields of the biosimilars landscape gathered in Amsterdam, the Netherlands, for the Biosimilars Commercialisation Summit 2019, a meeting dedicated to global issues in biosimilars market access. During the meeting, experts from around the globe discussed their experience with biosimilars and the opportunities and challenges that lie ahead.

Panel Discusses Effort by Administration to Lower Drug Prices

Allison Inserro

April 13 2019

During the last panel at the Alliance for Patient Access 4th Annual National Policy and Advocacy Summit on Biologics and Biosimilars, panelists discussed some of the administration’s proposals, such as moving Medicare Part B drugs to Part D, a proposal to end protected drug classes in Medicare, and the International Price Index.

Organization Discusses Impact of Nonmedical Switching on Patients

Allison Inserro

April 12 2019

Two leaders of the Alliance for Patient Access discussed results of a survey and focus group about nonmedical switching of patients from one drug to another by payers and pharmacy benefit managers for reasons of cost.

How Patient Advocates Engage Payers in Discussing Value

Allison Inserro

April 11 2019

The theme of the Alliance for Patient Access 4th Annual National Policy and Advocacy Summit on Biologics and Biosimilars meeting was all about value, and panelists from the Aimed Alliance and the Partnership to Advance Cardiovascular Health discussed how they used the concept of value in their discussions with payers.

Uptake of Biosimilars in the US: Good News, Bad News

Allison Inserro

April 10 2019

At the 4th Annual Policy and Advocacy Summit on Biologics and Biosimilars of the Alliance for Patient Access, speakers discussed the fact that while numerous biosimilars have been approved, most have not reached the market in the United States.

Biosimilars Benefit Patients With Expanded Access, but Physicians Still Need Education

Kelly Davio

March 29 2019

Patient access to treatment has improved in many countries since the advent of biosimilars, where access to biologic treatments is variable among nations and faces restrictions based on limitations to healthcare resources. During the Medicines for Europe 17th Biosimilar Medicines Conference, held March 28-29 in Amsterdam, the Netherlands, a panel of healthcare providers discussed this expanded access as well as other benefits that accrue to patients when biosimilars generate competition in the biologics market. They also considered lingering hurdles with provider education.

Are We Ready for Tailored Clinical Programs for Biosimilars?

Kelly Davio

March 29 2019

During the second day of the Medicines for Europe 17th Biosimilar Medicines Conference, held March 28-29 in Amsterdam, the Netherlands, a panel of experts discussed the current state of the regulatory landscape and considerations for tailoring clinical programs in the years ahead.

European Stakeholders Emphasize Multiwinner Tenders as Key to Competition

Kelly Davio

March 28 2019

During the opening day of the Medicines for Europe 17th Biosimilar Medicines Conference, held March 28-29 in Amsterdam, the Netherlands, a group of experts addressed successes, challenges, and learnings from biosimilar procurement processes.